This is a Cost Plus Fixed Fee contract awarded by the Defense Health Agency to Cellphire, Inc., a biotechnology company, for the development of a Cryopreserved Platelet (CPP) product for the U.S. Military. The total ceiling value of the contract is $63,949,124.00, and it is set aside for Total Small Businesses. The goal of the contract is to conduct the necessary research, development, and clinical trials to obtain Food and Drug Administration (FDA) licensure for the CPP product, which could provide an alternative to liquid platelets for military trauma situations. Cellphire has previously received federal contracts and grants from the Department of the Army and Defense Health Agency for work related to blood products, including lyophilized canine plasma and cryopreserved human platelets.
Generated 9/4/24, 9:12 AM